Andrew N. Schiff - Oct 17, 2022 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Oct 17, 2022
Transactions value $
-$862,109
Form type
4
Date filed
10/19/2022, 04:49 PM
Previous filing
Oct 11, 2022
Next filing
Oct 26, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Sale -$320K -19.9K -3.43% $16.05 562K Oct 17, 2022 By Aisling Capital IV LP F1, F2, F3
transaction ACRS Common Stock Sale -$542K -32.1K -5.71% $16.89 530K Oct 18, 2022 By Aisling Capital IV LP F1, F3, F4
holding ACRS Common Stock 0 Oct 17, 2022 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022.
F2 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
F4 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.23 to $17.1023, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.